Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02721433
Title 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA)
Recruitment Completed
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Ottawa Hospital Research Institute
Indications

prostate cancer

breast cancer

Therapies

Denosumab + pamidronate + Zoledronic acid

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.